United Therapeutics Corp (NASDAQ:UTHR) disclosed that its Chairperson and CEO, Martine A. Rothblatt, sold 9,500 shares of common stock on September 16, 2026, generating total proceeds of $4,763,172. The sale came immediately after Rothblatt exercised stock options for the same number of shares, with both transactions executed under a pre-arranged trading plan.
The option exercise allowed Rothblatt to acquire 9,500 shares at $117.76 per share, amounting to $1,118,720. These options had vested in equal installments between March 2021 and March 2023. The subsequent sale of the shares was conducted at prices ranging from $498.4505 to $505.2 per share, resulting in the reported total value.
All reported transactions were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025. This plan is set to continue until either 1,734,410 stock options are exercised or December 31, 2026, whichever comes first. Such plans are commonly used by executives to sell shares in a structured manner, avoiding potential conflicts with insider trading regulations.
Following these transactions, Rothblatt indirectly holds 324,443 shares of common stock through a family trust. Additional indirect holdings include shares held by spouse and other family trusts. The stock has since climbed to $595.66, up 29% over the past year, and is trading near its 52-week high of $614.23.
In other recent developments, United Therapeutics reported record third-quarter revenue of $832.5 million, surpassing Wall Street's estimate of $785.44 million. However, earnings per share came in at $5.71, falling short of the projected $6.21. The company highlighted strong demand for Tyvaso and other products, with Tyvaso revenue reaching $503.8 million, approximately 10% above consensus estimates.
Analyst responses to the revenue beat included Raymond James raising its price target to $720 from $717 while maintaining an Outperform rating. Wells Fargo adjusted its price target to $703 from $700, citing the outlook for interstitial lung disease (ILD) as a factor, and kept an Overweight rating. H.C. Wainwright increased its price target to $660, maintaining a Buy rating, and highlighted the company's multi-route pulmonary hypertension platform.
According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors seeking deeper insights can access a comprehensive Pro Research Report on UTHR, one of 1,400+ available reports transforming complex data into actionable intelligence.